TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Three Recent Biotech Activist Wins by Carl Icahn Michael Becker submits:Although a controversial topic, activist hedge funds and private equity firms typically use a small equity stake in an underperforming company to put public pressure on its management and board of directors with the goal of increasing stakeholder value through cost cutting, changes in corporate strategy or management, capital restructuring, asset divestiture and other tactics. Biotechnology investors with recent activist roles include Biotechnology Value Fund, Third Point LLC, Eastbourne Capital Management, and DellaCamera Capital Management among others. Perhaps the most prominent shareholder activist in biotechnology is billionaire investor Carl Icahn, largely through his Icahn Management LP investment fund. He has created value for some biotechnology stakeholders, including a very quick return with MedImmune, Inc. and a longer-term payoff with ImClone Systems, Inc.Complete Story » seekingalpha.com |
Senate Panel Debates Amendments The Senate Finance Committee debated health-care legislation for a second day Wednesday, adopting a couple of Democratic-backed amendments and turning down Republican ones. online.barrons.com |
The Deadly Mamba as a Lifesaver Researchers are hoping that desperately ill heart failure patients may find relief with the help of the eastern green mamba snake. online.wsj.com |
ISIS' Short-Term Trends Demonstrate When Technical Analysis Is Important The Curious Investor submits: This is a follow up to my post, “ISIS Pharmaceuticals breaches long term support.” As many of you may know, posts from this blog are often (though not always) syndicated on SeekingAlpha.com. In the case of my previous post on ISIS, I caught significant flack from the Seeking Alpha community. Among other things, I was accused of not understanding how to invest in biotech and generally missing the point on ISIS’ anti-sense technology. (For those interested, I actually posted on ISIS’ business and fundamental value in a previous post.) Well, I figure it’s time to post a follow up to my previous post. To recap, here is the chart I posted on October 5, 2009. This is a three-year weekly chart which I typically use to determine the intermediate/long term market trend driving the stock.Complete Story » seekingalpha.com |
Businesses Brace for Health Bill's Costs Companies are alarmed at potentially costly provisions in the Senate health-care bill, many of which they hope will be scrapped during negotiations next year. online.wsj.com |